Cloning and Expression of Recombinant Tick-Borne Encephalitis Virus-like Particles in Pichia pastoris

Seok-Min Yun, Young Eui Jeong, Eunbyeol Wang, Ye-Ji Lee, Myung Guk Han, Chan Park, Won-Ja Lee, WooYoung Choi,*

Division of Arboviruses, Korea National Institute of Health, Cheongju, Korea.
Division of Antimicrobial Resistance, Korea National Institute of Health, Cheongju, Korea.

Abstract
Objectives: The purpose of this study was to verify the feasibility of using the glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter based Pichia pastoris expression system to produce tick-borne encephalitis virus (TBEV) virus-like particles (VLPs).

Methods: The complementary DNA encoding the TBEV prM signal peptide, prM, and E proteins of TBEV Korean strain (KrM 93) was cloned into the plasmid vector pGAPZαA, then integrated into the genome of P. pastoris, under the control of the GAP promoter. Expression of TBEV VLPs was determined by Western blotting using monoclonal antibody against TBEV envelope (E) protein.

Results: Recombinant TBEV VLPs consisting of prM and E protein were successfully expressed using the GAP promoter-based P. pastoris expression system. The results of Western blotting showed that the recombinant proteins were secreted into the culture supernatant from the P. pastoris and glycosylated.

Conclusion: This study suggests that recombinant TBEV VLPs from P. pastoris offer a promising approach to the production of VLPs for use as vaccines and diagnostic antigens.

1. Introduction

Tick-borne encephalitis virus (TBEV) belongs to the Flavivirus genus of the Flaviviridae family and can cause fatal encephalitis in humans in Europe, Russia, and Far East Asia [1,2]. In South Korea, TBEV was first isolated from wild rodents in 2006 [3]. The flavivirus genome contains a single, long, open reading frame that encodes a polyprotein, which is cleaved into three structural proteins, i.e., the capsid (C), premembrane (prM) and envelope (E) proteins, and seven nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [4]. In flaviviruses, the prM and E proteins play crucial roles in the assembly and secretion of the virions [5–8]. Several studies have demonstrated that flavivirus virus-like particles (VLPs), consisting of
the prM and E proteins, have been shown to be similar to the native virions in the structural and functional features for infection [5.9–12]. Thus, flavivirus VLPs can be substituted for native virions in investigations into the biological features of flavivirus, such as vaccine study for the prevention of flavivirus-induced diseases.

Until recently, various expression systems, including mammalian cells and insect cells, have been used to produce TBEV VLPs as antigens [10,13,14].

_Pichia pastoris_ is one of the most widely used systems for producing recombinant protein by heterologous expression [15]. This system offers several advantages in comparison with other eukaryotic expression systems, such as the production of large-scale target proteins in their native conformation and cost-efficiency, and the proven safety of yeast-expressed VLPs vaccines such as hepatitis B virus VLPs [16] and human papillomavirus VLPs [17]. For this reason, the _P. pastoris_ expression system has been used for the production of flavivirus proteins including VLPs [18–21]. However, there are no reports on the production of TBEV VLPs from _P. pastoris_. In the current study, we investigated the expression of TBEV VLPs using the glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter-based _P. pastoris_ expression system.

To our knowledge, this is the first report on the successful expression of TBEV VLPs in _P. pastoris_.

2. Materials and methods

2.1. Viruses and cells

The TBEV Korean isolate, KrM 93 strain (GenBank accession No. HM535611), was propagated in the brains of suckling mice and BHK-21 cell as described previously [22]. The infected cell culture medium was used for RNA extraction.

2.2. Yeast strain and plasmid vector

The _P. pastoris_ host strain X33 (Invitrogen, Carlsbad, CA, USA) was used as the expression host in this study. The expression vector pGAPZαA (Invitrogen), which contains the selectable marker Zeocin (Invitrogen), is bifunctional in both _P. pastoris_ and _Escherichia coli_, the GAP promoter, and the alcohol oxidase I (AOX1) transcription termination regions. _E. coli_ transformants were selected on low salt Luria-Bertani agar plates containing 25 µg/mL Zeocin. _P. pastoris_ transformants were selected on YPDS plates (1% yeast extract, 2% peptone, 2% dextrose, 1M sorbitol, 2% agar, and 100 µg/mL Zeocin) and _P. pastoris_ liquid cell cultures were grown in YPD broth (1% yeast extract, 2% peptone, and 2% dextrose) with Zeocin.

2.3. Construction of recombinant expression vector

The coding sequence for the signal peptide of prM, prM, and E proteins was amplified from KrM 93 strain viral RNA by reverse transcription-polymerase chain reaction (RT-PCR) using SuperScript III first-strand synthesis system for RT-PCR (Invitrogen) and Ex Taq DNA polymerase (Takara, Shiga, Japan) according to the manufacturer’s instructions, and the following primers: KrM93SS-F 5'-GAC TTC GAA ATG GTT GGC TTG CAA AAA-3' (Bst BI site in bold and start codon in italics) and KrM93E-R 5'-GAA TCT AGA GCT GCC CCC ACT CCA AGG-3' (Xba I site in bold). The PCR product (named as 93prM-E) was first cloned into pCR 2.1-TOPO plasmid (Invitrogen) and then subcloned into pGAPZαA following enzymatic digestion using _Bst_ BI and _Xba_ I (New England Biolabs Inc., Beverly, MA, USA) to construct the full-length 93prM-E clone downstream of GAP promoter, which was designated as pGAPZαA/93prM-E (Figure 1A). The plasmid inserts were confirmed by DNA sequencing.

2.4. Yeast transformation

The plasmid pGAPZαA/93prM-E was linearized with Bgl II (New England BioLabs) and transformed into _P. pastoris_ X33 using _Pichia_ EasyComp Kit (Invitrogen) according to the manufacturer’s instructions. The transformed yeast cells were incubated in YPDS agar containing 100 µg/mL Zeocin at 30°C for 3–4 days. Zeocin-resistant yeast colonies were selected and identification of the insert in these Zeocin-resistant transformants was checked by colony PCR.

2.5. Expression of recombinant TBEV E protein in _P. pastoris_

Positive transformants, selected as described previously, were inoculated in 5 mL YPD broth with 100 µg/mL Zeocin with shaking (250 rpm) at 30°C overnight. These cultures were transferred to 500 mL of YPD broth with Zeocin with shaking (250 rpm) at 30°C for 48 hours. The culture supernatant and cell pellet were collected by centrifugation at 10,000 × _g_ for 10 minutes. The cell pellet was disrupted using Yeast PE LB (G-Biosciences, St. Louis, MO, USA) according to the manufacturer’s instructions. The lysate was clarified by centrifugation at 20,000 × _g_ for 30 minutes at 4°C. The culture supernatant was precipitated by using Amicon Ultra-15 Centrifugal Filter Units with 30 kDa membrane (Millipore, Billerica, MA, USA) according to the manufacturer’s instructions.

2.6. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analysis

The protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a reduced 4–12% Bis-Tris Gel (Invitrogen). Separated protein bands were transferred onto a 0.45-µm polyvinylidene difluoride membrane using the iBlot system (Invitrogen) according to the manufacturer’s instructions. The membrane was blocked with 5% skim milk in Tris buffered saline with 0.05%
Tween-20. TBEV E protein was detected using monoclonal anti-TBEV E antibody (8A7 mAb, in-house) as the primary antibody and horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (Promega, Madison, WI, USA) as the secondary antibody. The bands were visualized by enhanced chemiluminescence (GenDEPOT, Barker, TX, USA).

2.7. Analysis of glycosylation patterns of recombinant TBEV E protein

Glycosylation patterns of recombinant E protein in lysate and supernatant were analyzed by digestion using N-glycosidase F (PNGase F) and endoglycosidase H (Endo H; New England BioLabs) according to the manufacturer’s instructions. Glycosidase-treated protein samples were analyzed by SDS-PAGE and Western blotting as described previously.

3. Results

3.1. Construction of recombinant plasmid containing TBEV prM and E genes

The full-length prM and E genes of TBEV KrM 93 strain about 2 kb in size were amplified by using the RT-PCR method previously described. The 93prM-E fragment was then inserted into the yeast expression vector pGAPZαA to construct a recombinant plasmid pGAPZαA/93prM-E. The insert was confirmed by digestion with the restriction enzymes, Bst BI and Xba I (Figure 1B).

3.2. Expression of recombinant TBEV VLPS in P. pastoris

The pGAPZαA/93prM-E plasmid was transformed into P. pastoris and positive clones were selected. Yeast
cell lysate and culture supernatant were collected and analyzed for expression of E proteins by Western blotting using TBEV mAb 8A7. As shown in Figure 2, the specific recombinant E protein bands with a molecular mass of ~55 kDa were detected in both the lysate and supernatant, but not in the plasmid-alone control. This result demonstrated that the recombinant TBEV VLPs were secreted into the culture supernatant from the yeast cell.

The glycosylation state of E protein in TBEV VLPs were examined with Endo H, which is specific for high mannose-type oligosaccharides and PNGase F, which cleaves both high mannose- and complex-type oligosaccharides. Comparison of glycosidase-treated recombinant TBEV E protein from yeast cell lysate and culture supernatant by SDS-PAGE and Western blotting indicated that the recombinant E protein was glycosylated in the P. pastoris expression system (Figure 3).

4. Discussion

VLPs have been developed as effective vaccine candidates, because they mimic the organization and conformation of native virion without containing the viral full genome, and thus are a safe and highly immunogenic antigen. Among the various protein expression systems for VLPs production, the yeast expression system as an alternative eukaryotic expression system is a well-established platform for the efficient production of heterologous viral glycoproteins. Previous studies have reported that this system has been used for the generation of flaviviral glycoproteins [18–21]. Among the yeast expression systems, the protein expression level in the P. pastoris expression system was reportedly higher than that in another yeast Saccharomyces cerevisiae [23] and the GAP promoter based P. pastoris expression system can improve the protein yield compared to the P. pastoris by using methanol-inducible AOX1 promoter [24]. We therefore have selected the P. pastoris expression system under the control of the GAP promoter to produce the TBEV VLPs in this study.

Here, we demonstrated the efficient production of TBEV VLPs, consisting of the prM and E proteins by using the GAP promoter-based P. pastoris expression system. The KrM 93 strain, which belongs to the Western subtype of TBEV isolated in South Korea [22], was used for production of recombinant proteins. As a main structural protein of flavivirus, the E protein plays important roles in receptor binding, membrane fusion activity, and immunogenicity [25,26]. The prM gene was included in the recombinant plasmid pGAPZαA/93prM-E because E protein requires coexpression of the prM protein to maintain its native conformation and the protection of E protein from conformational alteration during transportation through the acidic compartments of the trans-Golgi network [27–29].

The results of Western blotting indicated that the TBEV VLPs were secreted into the culture supernatant from P. pastoris, suggesting that the signal peptide of prM can induce the secretion of TBEV VLPs, and coexpression of prM and E proteins in yeast cells may play an important role in virus particle release as shown in previous studies [5–9]. In addition, analysis of glycosylation of TBEV E protein in P. pastoris transformed with plasmid pGAPZαA/93prM-E showed that the recombinant E protein from P. pastoris was glycosylated by eukaryotic posttranslational modifications (Figure 3).

This is the first study to report the successful cloning and expression of TBEV VLPs by using the GAP promoter-based P. pastoris expression system, and this study demonstrated that recombinant TBEV VLPs from P. pastoris offer a promising approach to the production of VLPs for use as vaccines and diagnostic antigens. Further study will be required for the purification of TBEV VLPs from P. pastoris and to identify the immunogenicity in a mouse model.

**Figure 2.** Western blot analysis on the expression of tick-borne encephalitis virus E protein in Pichia pastoris. Lane 1 = plasmid alone control; Lane 2 = sample from the cell lysate; Lane 3 = sample from the culture supernatant.

**Figure 3.** Analysis of glycosylation of tick-borne encephalitis virus E proteins in Pichia pastoris transformed with plasmid pGAPZαA/93prM-E. Samples from (A) the cell lysate and (B) the cell supernatant were treated with Endo H (+) or PNGase F (+) and compared with untreated controls (−) by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting. ← = E protein; ← = deglycosylated E protein; Endo H = endoglycosidase H; PNGase = N-glycosidase F.
Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

This research was funded by an intramural grant from the Korea National Institute of Health (grant number 2013-NG53001-00).

References

1. Dumpis U, Crook D, Oksi J. Tick-borne encephalitis. Clin Infect Dis 1999 Apr;28(4):882–90.
2. Ecker M, Allison SL, Meixner T, et al. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J Gen Virol 1999 Jan;80(Pt 1):179–85.
3. Kim SY, Yun SM, Han MG, et al. Isolation of tick-borne encephalitis viruses from wild rodents, South Korea. Vector Borne Zoonotic Dis 2008 Spring;8(1):7–13.
4. Chambers TJ, Hahn CS, Galler R, et al. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990;44:649–88.
5. Allison SL, Stadler K, Mandl CW, et al. Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J Virol 1995 Sep;69(9):5816–20.
6. Kim JM, Yun SI, Song BH, et al. A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice. J Virol 2008 Aug;82(16):7846–62.
7. Mackenzie JM, Westaway EG. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 2001 Nov;75(22):10787–99.
8. Goto A, Yoshii K, Obara M, et al. Role of the N-linked glycans of the prM and E envelope proteins in tick-borne encephalitis virus particle secretion. Vaccine 2005 Apr 27;23(23):3043–52.
9. Wu CJ, Li TL, Huang HW, et al. Development of an effective Japanese encephalitis virus-specific DNA vaccine. Microbes Infect 2006 Sep;8(11):2578–86.
10. Schalich J, Allison SL, Stiasny K, et al. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and functional properties. Virus Genes 2010 Feb;40(1):53–60.
11. Konishi E, Mason PW. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J Virol 1993 Mar;67(3):1672–5.
12. Yoshii K, Hayakawa D, Goto A, et al. Enzyme-linked immunosorbent assay using recombinant antigens expressed in mammalian cells for serodiagnosis of tick-borne encephalitis. J Virol Methods 2003 Mar;108(2):171–9.
13. Liu YL, Si BY, Hu Y, et al. [Expression of tick-borne encephalitis virus prM-E protein in insect cells and studies on its antigenicity]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2005 Dec;19(4):335–9 [Article in Chinese].
14. Macauley-Patrick S, Fazenda ML, McNeil B, et al. Heterologous protein production using the Pichia pastoris expression system. Yeast 2005 Mar;22(4):249–70.
15. Leroux-Roels G, Desombere I, De Tollenaere G, et al. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults. Vaccine 1997 Nov;15(16):1724–31.
16. Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 2007 Apr 20;25(16):3001–6.
17. Kwon WT, Lee WS, Park PJ, et al. Protective immunity of Pichia pastoris-expressed recombinant envelope protein of Japanese encephalitis virus. J Microbiol Biotechnol 2012 Nov;22(11):1580–7.
18. Liu W, Jiang H, Zhou J, et al. Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties. Virus Genes 2010 Feb;40(1):53–60.
19. Sugrue RJ, Fu J, Howe J, et al. Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles. J Gen Virol 1997 Aug;78(Pt 8):1861–6.
20. Yun SM, Kim SY, Ju YR, et al. First complete genomic characterization of two tick-borne encephalitis virus isolates obtained from wild rodents in South Korea. Virus Genes 2011 Jun;42(3):307–16.
21. Chamberlain PA, Clegg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev 2000 Jan;24(1):45–66.
22. Vassileva A, Chugh DA, Swaminathan S, et al. Expression of hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris using the GAP promoter. J Biotechnol 2001 Jun 1;88(1):21–35.
23. McMinn PC. The molecular basis of virulence of the encephalitogenic flaviviruses. J Gen Virol 1997 Nov;78(Pt 11):2711–22.
24. Gritsun TS, Holmes EC, Gould EA. Analysis of flavivirus envelope glycoprotein functions. J Virol 1996 Jul;70(7):4549–57.
25. Heinz FX, Stiasny K, Puschner-Auer G, et al. Structural changes in the prM-E envelope glycoprotein of tick-borne encephalitis viruses from wild rodents, South Korea. Vector Borne Zoonotic Dis 2003 Mar;108(2):171–9.